About Johnson & Johnson

  • GRI

  • 2-1

    Organizational details

Our Business

Johnson & Johnson, through its Family of Companies (“the Company”), is the largest, most diversified healthcare products company, headquartered in New Jersey, U.S. Our operating companies employ approximately 153,700 employees4 in virtually all countries of the world, who are engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. We work with more than 46,000 suppliers and hundreds of external manufacturers to support the development and manufacturing of our products worldwide. The Company’s product portfolio includes thousands of Pharmaceutical, MedTech and Consumer Health products that address the health and wellness needs of people every day.

Our Purpose

We blend heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Our Values

We are driven by Our Credo, a set of values and principles that, since 1943, has challenged and inspired us to put the needs and well-being of the people we serve first.


Cardiovascular, Metabolism & Retina


Infectious Diseases & Vaccines



Pulmonary Hypertension


Interventional Solutions


Surgery (General & Advanced)


Consumer Health*

Baby Care

Oral Care

Over-the-Counter Medicines

Skin Health/Beauty

Women’s Health

Wound Care

Sales by Business Segment (Millions)

MedTech Consumer Health * Pharmaceutical $52,563 $27,427 $14,953 MedTech Consumer Health * Pharmaceutical $52,563 $27,427 $14,953
* In November 2021, the Company announced its intention to separate the Company’s Consumer Health business into a new, publicly traded company. In September 2022, Kenvue was announced as the name for the planned New Consumer Health Company. Kenvue was part of Johnson & Johnson for all of 2022 (the reporting period for this 2022 Health for Humanity Report). Kenvue completed an initial public offering of 198,734,444 shares of its common stock on May 8th, 2023. As of the closing of the initial public offering, the Company owns approximately 89.6% of the total outstanding shares of Kenvue common stock. The Company remains on track to complete the separation in 2023, subject to market conditions.

Financial Results (Millions)

Johnson & Johnson is a publicly owned corporation with stock traded on the New York Stock Exchange (NYSE:JNJ).

$ millions 2021 2022 Total sales R&D investment Net earnings $94,943 $93,775 $14,603 $14,714 $17,941 $20,878 Market price per share (year-end close) $176.65 Consecutive years of dividend increases * 61 $ millions 2021 2022 Total sales R&D investment Net earnings $94,943 $93,775 $14,603 $14,714 $17,941 $20,878 Market price per share (year-end close) $176.65 Consecutive years of dividend increases * 61
* Includes dividend declared in April 2023.

4 Abiomed headcount is not included in this total employee number due to year-end acquisition timing and our Human Resources Information System integration processes.